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ABSTRACT 
The purpose of this research is to automatically recognize names in biomedical documents.  
First, we analyze characteristics of biomedical names.  Then, we propose a rich set of 
features, including orthographic, morphological, part-of-speech and semantic trigger 
features.  All these features are integrated via a Hidden Markov Model with back-off 
modeling.  Finally, we propose a method for biomedical abbreviation recognition and two 
methods for cascaded name recognition.  Evaluation on GENIA corpus V3.02 and V1.1 
shows our system achieves 66.5 and 62.5 F-measure respectively.  It shows that our 
system outperforms previous best published system on the same V1.1 by 8.1 F-measure.  
The major contribution of this thesis lies in its detailed analysis of biomedical names, the 
rich feature set and the effective methods for cascaded name recognition.  To our best 
knowledge, our system is the first one that resolves the phenomena of cascaded 
biomedical names.  In addition, a demo has been put on the web. 





I would like to express my great gratitude to my supervisor Dr. Zhou Guodong, my 
supervisor A/P Tan Chew Lim, and Dr. Su Jian for their advice, guidance and support 
throughout the duration of my postgraduate study.  They have been always accessible and 
holding discussion and meetings periodically.  Their insightful opinions are very 
important to this thesis. 
 
I also thank the Department of Computer Science, School of Computing, NUS and 
Institute for Infocomm Research for providing me the opportunity and financial support to 
study in NUS.  
 
I would like to thank my parents and Miss Shen Dan for their concern, help and support.  
Without them, I would never be able to fulfill my study.  I also thank my lab-mates Mr. 
Hong Huaqing, Mr. Yang Xiaofeng and other friends for their discussion and help. 
 iii
 TABLE OF CONTENTS 
 
 
SUMMARY ...................................................................................................................... vii 
LIST OF TABLES .............................................................................................................ix 
LIST OF FIGURES ............................................................................................................x 
 
1 INTRODUCTION....................................................................................................... - 1 - 
1.1 Motivation .......................................................................................................... - 1 - 
1.2 Background ........................................................................................................ - 2 - 
1.3 Related Work...................................................................................................... - 3 - 
1.3.1 Rule-based Approaches ........................................................................... - 4 - 
1.3.2 Machine-Learning Approaches................................................................ - 6 - 
1.4 Our Contribution ................................................................................................ - 9 - 
1.5 Organization of the Thesis ............................................................................... - 11 - 
 
2 CHARACTERISTICS OF BIOMEDICAL NAMES............................................ - 12 - 
2.1 Length............................................................................................................... - 12 - 
2.2 Naming Conventions........................................................................................ - 13 - 
2.3 Descriptive Names ........................................................................................... - 14 - 
2.4 Cascaded Names............................................................................................... - 14 - 
2.5 Complicated Constructions .............................................................................. - 15 - 
2.6 Abbreviations ................................................................................................... - 16 - 
 iv
  
3 FEATURES ............................................................................................................... - 18 - 
3.1 Orthographic Features ..................................................................................... - 18 - 
3.2 Morphological Features.................................................................................... - 20 - 
3.3 Part-of-Speech Features ................................................................................... - 21 - 
3.4 Semantic Trigger Features................................................................................ - 23 - 
3.4.1 Head Noun Triggers............................................................................... - 23 - 
3.4.2 Special Verb Triggers ............................................................................ - 25 - 
 
4 METHODOLOGY ................................................................................................... - 26 - 
4.1 Hidden Markov Model ..................................................................................... - 26 - 
4.2 Hidden Markov Model-based Name Recognizer............................................. - 26 - 
4.3 Abbreviation Recognition ................................................................................ - 28 - 
4.4 Cascaded Name Recognition............................................................................ - 32 - 
4.4.1 Post-Processing Rule-based Approach .................................................. - 32 - 
4.4.2 HMM-based Iterative Recognition Approach ....................................... - 34 - 
4.5 Work Flow of Biomedical Name Recognition................................................. - 38 - 
 
5 EXPERIMENTATION ............................................................................................ - 39 - 
5.1 Data set ............................................................................................................. - 39 - 
5.1.1 GENIA corpus V1.1 .............................................................................. - 39 - 
5.1.2 GENIA corpus V2.1 .............................................................................. - 39 - 
5.1.3 GENIA corpus V3.02 ............................................................................ - 40 - 
5.2 Experiments for Biomedical Name Recognition.............................................. - 40 - 
 v
 5.2.1 Experiment Settings............................................................................... - 40 - 
5.2.2 Experiment Results ................................................................................ - 40 - 
5.2.3 Effectiveness of Feature Sets................................................................. - 42 - 
5.2.4 Effectiveness of Methods for Abbreviation and Cascaded Names........ - 45 - 
5.2.5 Effect of Training Data Size .................................................................. - 47 - 
5.3 Error Analysis................................................................................................... - 47 - 
5.3.1 False Positive ......................................................................................... - 48 - 
5.3.2 False Negative........................................................................................ - 49 - 
5.3.3 Misclassification .................................................................................... - 49 - 
5.3.4 Modifier-caused Error............................................................................ - 49 - 
5.3.5 Cascaded-annotation-caused Error ........................................................ - 50 - 
5.3.6 Miscellaneous Error ............................................................................... - 51 - 
5.3.7 Summary of Error Analysis ................................................................... - 51 - 
 
6 CONCLUSION ......................................................................................................... - 52 - 
6.1 Conclusions ...................................................................................................... - 52 - 
6.2 Future Work ..................................................................................................... - 53 - 
6.3 Dissemination of Results.................................................................................. - 54 - 
 
REFERENCES............................................................................................................. - 55 - 
APPENDIX................................................................................................................... - 60 - 
 
 vi
  SUMMARY 
 
Biomedical name recognition is to recognize names of entities and concepts in biomedical 
documents.  This task is critical for information extraction and knowledge mining in the 
biomedical domain.  In the last few years, various hand-written rule-based and machine 
learning approaches have been studied in this field.  Among them, most approaches are 
adapted from the previous MUC named entity recognition task in the newswire domain.  
However, biomedical names have special characteristics, such as long length distribution, 
complex naming conventions, various constructions, etc., which are quite different from 
name entities in the newswire domain.  In this thesis, we first analyze these characteristics 
in the biomedical domain and compare them with the entity names in the newswire 
domain.  Then, we propose various features, such as orthographic, morphological, part-of-
speech, and semantics trigger features to deal with the special characteristics in the 
biomedical names.  Especially, we adapt a part-of-speech tagger to the biomedical domain 
and find that proper adaptation makes a big difference in biomedical name recognition.  
Finally, we present a method for biomedical abbreviation recognition and two methods for 
cascaded name recognition which are new to this field.  All the features and the methods 
are integrated via a Hidden Markov Model with back-off modeling.  Extensive 
experiments have been done on the GENIA corpus V3.02 to show the effectiveness of our 
rich feature set, part-of-speech feature adaptation, and proposed methods on different 
training data sizes.  It shows that the orthographic feature, the morphological feature, the 
part-of-speech feature adapted into the biomedical domain and the head noun trigger 
feature are useful for biomedical name recognition, while the special verb trigger feature 
 vii
 cannot lead to positive effect in our model.  It also shows that our proposed methods for 
abbreviation recognition and cascaded name recognition are effective.  In addition, our 
system outperforms previous best published system by 8.1 f-measure on the same GENIA 
corpus V1.1 without using any dictionary.  Finally, a detailed error analysis is done and 
shows that about 46% of errors come from inconsistent annotation in the corpus.  It 
suggests that a much higher performance can be expected with a more consistent corpus.   
  
 viii
 LIST OF TABLES 
 
Table 2.1 Statistics on different annotation constructions from GENIA 
corpus V3.02 
15
Table 3.1 Sorted list of orthographic features by descending order of 
priority 
19
Table 3.2 Examples of morphological features 21
Table 3.3 Performance comparison between part-of-speech taggers using 
training data in different domains 
23
Table 3.4 Examples of auto-generated unigram and bi-grams head noun 
triggers for 4 classes 
24
Table 3.5 20 top frequent special verb triggers 25
Table 4.1 Patterns of cascaded names 33
Table 4.2 Examples of post-processing rules for cascaded name 
recognition 
33
Table 5.1 Experiment settings for biomedical name recognition on GENIA 
corpus V1.1 and V3.02 
40
Table 5.2 Overall performance of biomedical name recognition on GENIA 
corpus V3.02 and V1.1, comparing to [Kazama et al. 2002] on 
GENIA corpus V1.1 
41
Table 5.3 Results for biomedical name recognition of each name class on 
GENIA corpus V3.02. 
42
Table 5.4 Experiment results for biomedical name entity recognition by 
using different combinations of features 
43
Table 5.5 Effect of adaptation of POS tagger on biomedical name 
recognition 
44
Table 5.6 Effectiveness of abbreviation recognition method and two 
cascaded name recognition methods 
46
Table 5.7 Statistics of error types for biomedical name recognition by 
sampling 100 error instances 
48
 ix
 LIST OF FIGURES 
 
Figure 2.1 Length distribution of biomedical names in GENIA corpus 
V3.02 
12
Figure 2.2 Length distribution of named entities in MUC-7 corpus 12
Figure 4.1 Biomedical abbreviation recognition algorithm 31
Figure 4.2 Algorithm of HMM-based iterative recognition approach for 
cascaded name recognition 
36
Figure 4.3 Algorithm of a generalized recursive method for all-level 
cascaded name recognition 
37
Figure 4.4 Flowchart of biomedical name recognition 38
Figure 5.1 Effect of using special verb triggers on biomedical name 
recognition 
44
Figure 5.2 Effect of training data size for biomedical name recognition 47









With the exploding amount of literatures in the biomedical domain, it becomes more and 
more difficult for people to deal with such a huge amount of text resources.  Intelligent 
techniques must be developed to alleviate human work.  As an essential one of these 
techniques, name entity recognition (NER) automatically identifies names from texts and 
classifies them into predefined classes.  The task of named entity recognition was defined 
by the Message Understanding Conferences (MUC), which recognizes names of entities 
such as PERSON, ORGANIZATION, LOCATION and etc in the newswire domain.  In the 
biomedical domain, not only the names of entities, such as protein, gene and virus, but 
also the names of some concepts, such as names of biomedical process, are needed to be 
recognized.  Therefore, we use the term “biomedical name recognition” for the named 
entity recognition task in the biomedical domain so as to be more general.   Biomedical 
name recognition can be widely applied in: 
1) Text Mining in the biomedical domain (e.g. protein-protein interactions from 
literature) 
2) Information Extraction  
3) Information Retrieval 
4) Biomedical Databases (e.g. automatic database building and updating) 
5) Question & Answering 
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Chapter 1: Introduction 
Previous research work of named entity recognition in MUC got some promising results 
in the newswire domain.  However, due to special characteristics in the biomedical 
domain, traditional named entity recognition techniques fail to achieve satisfactory results 
in biomedical name recognition.  The purpose of our work is to study the special 




The Message Understanding Conferences (MUC), sponsored by DARPA in the U.S.A., 
defined the task of named entity recognition.  The task consists of three subtasks including 
recognition of named entity, temporal expression and number expression.  Among the 
three subtasks, the named entity subtask recognizes person names, location names and 
organization names; the temporal expression subtask recognizes date and time expressions; 
and the number expression subtask recognizes quantity expressions of monetary values 
and percentages.  Generally speaking, the named entity recognition task can be regarded 
as a combination of two procedures: entity identification and entity classification.  Entity 
identification tries to find the boundaries of all named entities and entity classification 
assigns a type for each identified instances.   
 
In the early days of named entity recognition, people mainly relied on the manually 
written rules and pattern-matching techniques.  The LTG system for MUC-7 [Mikheev et 
al. 1998] uses 5 phase probabilistic partial matching rules for the named entity subtask and 
a special developed grammar and compiled lists for the temporal and numeric subtasks.  
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The NetOwl Extractor System [Krupka and Hausman 1998] recognizes named entities 
based on lexicons and pattern rules.  The LaSIE-II system described in [Humphreys et al. 
1998] also makes use of hand-coded rules.  Although most of these systems get quite high 
performance, they relied much on manual work and adapting them to a new domain is 
normally time-consuming and very expensive. 
 
Besides hand-coded rule-based approaches, there are more and more studies using 
machine-learning techniques for named entity recognition.  Many machine learning 
approaches have been applied in the task of named entity recognition, including 
Maximum Entropy (ME) [Borthwick et al. 1998; Chieu and Ng 2002], Hidden Markov 
Models (HMM) [Miller et al. 1998; Bikel et al. 1999; Yu et al. 1998; Zhou and Su 2002], 
Decision Trees and Support Vector Machines (SVM).  Along with them, many research 
works have been exploring various features for named entity recognition.  [Chieu and Ng 
2002] made use of the global information.  [Zhou and Su 2002] presented an effective 
constraint relaxation algorithm for solving data sparseness problem in order to integrate 
rich feature sets.  Comparatively speaking, machine learning approaches are more capable 
of adaptation and cheaper for maintenance. 
 
 
1.3 Related Work 
This section presents a review of recent literatures on biomedical name recognition.  With 
fast development in the research field of biology and life science, there are more and more 
research projects on biomedical name recognition.  Some of them are adapted from the 
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previous MUC systems.  From the methodological point of view, all of them can be 
grouped into rule-based and machine learning-based. 
 
1.3.1 Rule-based Approaches 
As for rule-based approaches, the representative research efforts include [Fukuda et al. 
1998], [Proux et al. 1998] and [Gaizauskas et al. 2000].   
 
[Fukuda et al. 1998] proposed a method called PROPER (Protein Proper-noun phrase 
Extracting Rules), which attempted to identify protein names from biomedical documents 
based on surface clues of character strings, such as the presence of upper cases and special 
characters.  They summarized the nomenclature of protein names into three categories 
based on the surface characteristics of word.  They defined strings with special 
orthographic patterns as “core-terms”, such as string with capital letters, digits and special 
symbols.  They also defined a list of keywords called “f-terms (feature-terms)” to 
determine functions or to compose compound words.  From our understanding, the “f-
terms” are basically the head nouns of compound protein names.  The method identifies 
protein names in two phases.  First, it extracts “core-terms” from tokenized texts by five 
hand-written rules.  Second, it concatenates “core-terms” and “f-terms” by rebuilding 
“core-blocks” and “dependency-blocks”.  Every “core-block” is a noun phrase without 
conjunctions and prepositions, which was concatenated by “core-terms” and “f-terms” 
using a series of rules.  Every “dependency-block” is a block between “core-blocks”, 
which basically solves conjunction problem.  The evaluation on 30 annotated MEDLINE 
abstracts on SH3 domain achieved precision of 91.90% and recall of 93.32%.   
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[Proux et al. 1998] detected gene names in biomedical documents based on lexical and 
morphological information.  Their system made use of a tagger based on the finite state 
technology to conduct a lexical and morphological analysis of each word in the first level.  
The tagger tokenizes sentences, conducts a lexical lookup to process a morphological 
analysis and performs part-of-speech tagging.  Each word in the sentence is given various 
tags and a special flag.  The tags include noun, proper noun and abbreviation, etc.  The 
special flag indicates whether the word matches a known word or is “guessed”.  Based on 
the tags and the special flag, they built a series of rules including recovery rules, 
algorithmic rules and contextual rules.  The recovery rules recognize gene names using a 
domain-specific dictionary containing about 200 general biological expressions.  The 
algorithmic rules recognize gene names based on prefixes (nearly 100 entries), suffixes 
(nearly 200 entries) and complex expressions such as nucleotide sequences and peptide 
notations.  The contextual rules apply lexical-syntactic patterns to make final validations 
on candidates.  Their system achieved precision of 91.4% and recall of 94.4% on a small 
corpus (1200 sentences) from FlyBase.  However, they found that when they applied the 
system to a larger corpus (25,000 MEDLINE abstracts) and evaluated the performance by 
sampling, the precision was reduced to around 70%.   
 
[Gaizauskas et al. 2000] derived their system from an already developed IE system in the 
MUC.  Their system was applied in two projects: extraction of information about enzymes 
and metabolic pathways (EMPathIE) and extraction of information about protein structure 
(PASTA).  Their system consisted of five processing stages: text processing, 
morphological analysis, term lookup, terminology parsing and term matching.  The main 
information resources they used included case-insensitive terminology lexicons (the 
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component term of various categories) such as resources from public databases (SWISS-
PROT, CATH and SCOP), morphological cues (standard biochemical suffixes) and hand-
constructed grammar rules for each terminology class.  The EMPathIE system was 
designed for 10 named entity classes, such as compound, element, enzyme, etc. and 
achieved precision of 86% and recall of 68% on 6 full journal articles.  The PASTA 
system was designed for 13 named entity classes, such as protein, species, residue, etc. 
and achieved precision of 94% and recall of 88% on 52 MEDLINE abstracts.   
 
Although these rule-based systems seem quite promising, they lack the ability of 
adaptation to new name classes in biomedical domain.  Once a new name class is required 
to identify, a set of rules for the new class has to be generated manually.  In fact, with the 
increasing number of name classes, the terms of entity names in different classes will 
overlap each other.  Consequently, the more the number of classes is, the more difficult to 
construct the consistent rules.  Moreover, up to now, the evaluations of these systems are 
only based on small corpus.  [Proux et al. 1998] reported their system fails in a larger 
corpus.  It seems that the rule-based system is not that robust and flexible.  
 
1.3.2 Machine-Learning Approaches 
Currently, machine learning-based approaches become more and more popular in 
biomedical name recognition.  The typical works include [Nobata et al. 1999], [Collier et 
al. 2000], [Takeuchi and Collier 2002], [Kazama et al. 2002] and [Lee et al. 2003].   
 
[Nobata et al. 1999] tried two classification methods and three identification methods for 
biomedical name recognition.  The first classification method tried to induce a Naïve 
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Bayes classifier using conditional probabilities between word and class from the 
distribution of words in pre-classified domain-specific word lists.  The second 
classification method used a decision tree approach which incorporated feature sets of 
part-of-speech information, character type information, and domain specific word lists.  
The three identification methods included shallow parsing, decision trees and statistical 
identification.  The system tried to recognize 10 classes of biomedical names, such as 
protein, DNA, RNA, cell line, cell type, etc.  They conducted a series of experiments by 
combination of each classification and identification method.  The experiments showed 
that by using both decision tree methods for classification and identification achieved the 
best f-score of 56.98 to 66.24 on 100 manually annotated MEDLINE abstracts by 5-fold 
cross validation.  The corpus was a preliminary version of GENIA corpus. 
 
[Collier et al. 2000] applied linear interpolating HMM for gene name and gene product 
name recognition.  They trained HMM entirely based on surface word itself and character 
information.  The system tried to recognize 10 classes of biomedical names.  The classes 
and the corpus were the same as those in [Nobata et al. 1999].  The system achieved f-
score of 72.8.   
 
[Takeuchi and Collier 2002] did their experiment based on SVM.  The model incorporated 
surface word, orthographic feature and the class assignments of context words.  The 
window size of context was -3 to +3.  In their experiment, they found that part-of-speech 
features degraded the performance in their model.   The evaluation was also conducted on 
the same corpus as used in [Nobata et al. 1999] and the f-score was 71.78.   
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[Kazama et al. 2002] developed a system also based on SVM.  To our knowledge, it is one 
of the earliest published works on the GENIA corpus V1.1, which contains 670 
MEDLINE abstracts and 24 named entity classes.  Compared with [Nobata et al. 1999], 
they made use of richer features, such as word feature, part-of-speech feature, prefix 
feature, suffix feature, previous class feature, word cache feature and HMM state feature.  
They use a BIO (beginning/in/out of entity name) representation to classify a word.  For 
example, a word belongs to class “B-DNA” if it is a beginning of a DNA name; a word 
belongs to class “I-Protein” if it is inside a protein name; and a word belongs to class “O” 
if it is outside a entity name.  They tried to classify each word into one of such categories 
to represent the name recognition.  Since standard SVM model is a binary classifier, the 
pair-wise strategy was used for constructing a multi-class SVM.  In addition, they used a 
class splitting technique for balancing class distribution.  Since there were too much 
samples of class “O”, they combined class “O” and part-of-speech tags, and thus split 
class “O” into several subclasses, such as “O-NN”, “O-JJ” and etc.  They divided the 670 
abstracts in GENIA corpus V1.1 into a training set of 590 abstracts and a test set of the 
rest 80 abstracts.  Their system achieved f-score of 54.4. 
 
[Lee et al. 2003] developed a two-phase system based on SVM.  The main idea of their 
work was to separate the name recognition procedure into two phases: identification and 
classification.  They trained an SVM model for name identification, which is to find the 
locations of all the names.  After the identification phase, they trained another SVM model 
for name classification, which is to classify the identified names.  The feature set for name 
identification consisted of part-of-speech, suffix, prefix and surface word.  The feature set 
for name classification consisted of functional words, inside words, left context words and 
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right context words.  They conducted experiments both on GENIA corpus V1.1 and V3.0p.  
However, the part-of-speech information they used in their experiments was from the 
annotated corpus instead of some automatic part-of-speech tagger.  This could result in the 
unpersuasive comparisons between their results and the others’.   
 
Certainly, it is difficult to compare various models because of the different classes and 
corpus they used.  Considering [Nobata et al. 1999], [Collier et al. 2000] and [Takeuchi 
and Collier 2002] using the same class and corpus, we make a rough comparison among 
them.  The results show that HMM and SVM outperform decision tree and the 
performance of HMM and SVM are almost equivalent.  The results also show that how to 
capture the useful evidence for domain-specific names and how to integrate them 
effectively in the model is crucial.  In this respect, [Collier et al. 2000]’s HMM model 
only use surface word and character information, which may not be adequate for coping 
with the complicated biomedical names. 
 
 
1.4 Our Contribution 
Our contribution to the research in biomedical name recognition can be concluded as 
follow.   
 
Firstly, we provide a detailed analysis of the characteristics of biomedical names as well 
as the statistics-based comparisons between name recognition in the newswire domain 
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(MUC) and the biomedical domain.  Among these, the analyses of the length distribution 
and the cascaded name are the author’s contributions. 
 
Secondly, we develop a rich set of features for our Hidden Markov Model-based name 
recognizer for the biomedical domain.  We also conduct a series of experiments to 
evaluate the impact of different features.  Especially for the part-of-speech feature, we 
adapt a part-of-speech tagger into the biomedical domain to get more accurate part-of-
speech feature and present the necessity of such adaptation by comparisons.  Among these 
contributions, the design of the orthographic features, morphological features and the 
adaptation of the part-of-speech tagger are the author’s contributions. 
 
Thirdly, our system is the first that tries to resolve the phenomena of cascaded names in 
the biomedical domain.  In this thesis, two solutions are proposed: a post-processing rule-
based approach and an HMM-based iterative recognition approach.  The cascaded name 
recognition is the author’s contribution. 
 
In addition, we make a detailed error analysis, from which we can have certain 
observations for potential improvement in the future.  Last but not least, we build a 
concrete system for biomedical name recognition.  The experimental results show that our 
system outperforms the previous best published system by 8.1 f-measure on the same 
training and test data of GENIA corpus V1.1.  Demo of our work can also be accessed at 
http://textmining.i2r.a-star.edu.sg/NLS/demo.htm.  Among these, a part of the error 
analysis, about half of the system development and the development web demo are the 
author’s contributions. 
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1.5 Organization of the Thesis 
The thesis is organized as follows: Chapter 2 provides a detailed analysis of special 
characteristics of biomedical names.  In Chapter 3, the rich feature set that we design for 
the biomedical domain is described in detail.  In Chapter 4, we provide detailed 
description of our hidden Markov model-based name recognition model and present 
various methods for abbreviation recognition and cascaded name recognition.  In Chapter 
5, we show our experimental configurations and various experimental results.  We also 
make analysis based on these results and present error analysis.  Finally, in Chapter 6 we 
conclude this thesis with future works. 
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Chapter 2 
CHARACTERISTICS OF BIOMEDICAL NAMES 
 
2.1 Length 
The length distribution of biomedical names is different from that of named entities in the 
newswire domain.  We found that the variance of length of biomedical names is wider.  In 
the biomedical documents, many names are very long, e.g. “47 kDa sterol regulatory 
element binding factor”.  Most of named entities in the newswire domain are 
comparatively short and have less variance of length.  We produced statistics on the length 
of biomedical names from GENIA corpus, as well as the length of entity names in 
newswire domain from the MUC-7 corpus.  Figure 2.1 and Figure 2.2 show the length 
distributions of biomedical names and newswire named entities respectively. 












1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Num. of names
 
Figure 2.1: Length distribution of biomedical names in GENIA corpus V3.02 
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Figure 2.2: Length distribution of named entities in MUC-7 corpus 
 
 - 12 -
Chapter 2: Characteristics of Biomedical Names 
From Figure 2.1 and Figure 2.2, we can find that the average length of biomedical names 
is 2.48, which is greater than that of newswire named entities (1.60).  In addition, 
newswire named entities with length over six are rare, while many biomedical names 
consist of more than 10 words.  The standard deviation of length for biomedical names is 
1.46, which is also much greater than that for newswire named entities (0.94). 
 
2.2 Naming Conventions 
One biomedical name may be found in various spelling forms, for example, “N-
acetylcysteine”, “N-acetyl-cyteine”, and “NAcetylCysteine”.  We find that the use of 
capitalization and hyphen is casual in biomedical documents.  Naming conventions are 
inconsistent.  On the other hand, capitalization of entity name is different between 
biomedical domain and newswire domain.  We produced statistics on capitalization in 
entity names.  From GENIA corpus V3.02, we find that 62.89% of words in biomedical 
names are in lowercase. However, from MUC-7 corpus, we find that only 1.65% of words 
in named entities are in lowercase.  Therefore, the feature of capitalization in the 
biomedical domain is not as dominant as it in the newswire domain for named entity 
recognition. 
 
Moreover, more and more biomedical names are constantly invented by authors and have 
not been collected by public databases.  This may result in the inadequate coverage in 
some domain-specific dictionaries [Fukuda et al. 1998] [Nobata et al. 1999].  Thus, 
conventional named entity recognition methods which depend on pre-defined dictionaries 
may not perform well. 
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2.3 Descriptive Names 
Sometimes, biomedical names are descriptive.  Modifiers often occur before or after basic 
names to indicate property, type, nature and etc.  In some cases, people disagree with each 
other on whether modifiers should be regarded as part of the names.  That causes much 
inconsistency in the training data.  For example, in “normal thymic epithelial cells”, it is 
hard to decide whether the word “normal” should be the beginning of the name.  
 
Compared to biomedical domain, few named entities are descriptive in newswire domain.  
Named entities in newswire texts are mostly proper names.  Even though descriptive 
words exist, people are only interested in the basic named entities.  
 
2.4 Cascaded Names 
Biomedical names can be compound names.  One name may be embedded in another 
name, e.g. “<PROTEIN><DNA>kappa 3</DNA> binding factor</PROTEIN>”.  Some names 
have more than one level of cascaded-annotation, such as “<OTHERNAME> 
<DNA><VIRUS>HIV-2</VIRUS>enhancer</DNA> activation</OTHERNAME>”.  We produced 
statistics on different annotation construction, including non-cascaded-annotation, 
cascaded-annotation, and complicated construction (to be discussed in the next section), 
from GENIA corpus V3.02 (Table 2.1).  From Table 2.1, we can find that 16.57% of 
names are cascaded-annotated and distributed over all the name classes.  The ideal 
biomedical name recognition requires all instances of entity names be recognized, 
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including the embedded ones.  While in practical ways, people only recognize the longest 
names. 
 
In the newswire domain, only person names and location names may be embedded in 
other entity names, e.g. “Eastern China Airlines”.  However, as stated in the section 
“Nested Expressions” of the MUC guidelines for markup of exceptional constructions, 
once a person name or a location name is embedded in another name, it will be regarded 
as a part of that longer name and won’t be annotated separately. 
Annotation Construction Percentage 
Non-cascaded-annotated names 81.37% 
Cascaded-annotated names 16.57% 
Name with complicated constructions  2.06% 
Table 2.1: Statistics on different annotation constructions from 
GENIA corpus V3.02 
 
 
2.5 Complicated Constructions 
In the biomedical domain, authors often use conjunction “and” and disjunction “or” in 
order to reduce redundancy.  Two or more biomedical names may share one head noun.  
For example, “91 and 84 kDa proteins” consists of two names: “91 kDa proteins” and 
“84 kDa proteins”.  Strictly speaking, it is required to recognize the two names separately.  
Some instances have more specific construction, e.g. “IL-2- but not IL-12-stimulated NK 
cells”.  According to our statistics on GENIA corpus V3.02, 2.06% of biomedical names 
have such complicated construction, which has been shown in Table 2.1.   
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In the newswire domain, the section “Expressions Involving Elision” of the MUC 
guidelines for markup of exceptional constructions defined a standard for annotating 
complication constructions.  However, these constructions have much less cases in the 
newswire domain.   
 
2.6 Abbreviations 
Abbreviations in the biomedical domain pose much bigger challenge to name recognition 
than that in the newswire domain for several reasons: 
 
First, abbreviations in the biomedical domain are frequently used.  [Chang et al. 2002] 
showed that, in all MEDLINE abstracts until the end of 2001, 42.8% abstracts have at 
least 1 abbreviation and 23.7% abstracts have two or more.  They also showed that there is 
one new abbreviation in every 5-10 abstracts on average and the growth rate of new 
abbreviation is increasing.  Moreover, abbreviations in the biomedical domain are well 
distributed in all classes, while in the newswire domain, abbreviations just occur in some 
classes, such as PERSON, ORGANIZATION, and rarely occur in other classes, such as 
TIME, PERCENT and MONEY.  Therefore, the performance of the abbreviation 
recognition in the biomedical domain has greater impact on the overall performance. 
 
Secondly, abbreviations in biomedical domain are formed irregularly.  For instance, 
abbreviations may be combined from the first letters of words in the full form, e.g. Human 
Immunodeficiency Virus (HIV), or a subset of syllable boundaries, e.g. Interleukin 2 (IL2), 
or several contiguous characters of a word, e.g. palate (PAL), etc.  It highlights the 
 - 16 -
Chapter 2: Characteristics of Biomedical Names 
difficulties to build relationships between abbreviations and their full forms.  While in the 
newswire domain, abbreviations are comparatively regular.  Most abbreviations are 
formed by the first letters of words in the full forms, e.g. IBM, US, etc. 
 
Thirdly, abbreviations in biomedical domain are highly ambiguous.  For instance, TCF 
may refer to T cell Factor or Tissue Culture Fluid in different biomedical documents.  
[Liu et al. 2002] show that 81.2% of the abbreviations are ambiguous and have an average 
of 16.6 senses in MEDLINE abstracts.  Name class of abbreviation depends on context 
and cannot be simply assigned by matching items in abbreviation dictionaries collected 
from public resources. 
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3.1 Orthographic Features (Fo) 
Orthographic features are designed to capture the word formation information, such as 
capitalization, digitalization and their combinations.  Orthographic information have been 
widely used in name recognition with different design of features, such as [Zhou and Su 
2002], [Nobata et al. 1999], [Gaizauskas et al. 2000], [Collier et al. 2000], [Takeuchi and 
collier 2002], and [Kazama et al. 2002].  Basically, orthographic features are manually 
designed and aim to group words by similar formation.   
 
In the newswire domain, orthographic features are both helpful to identify locations and 
distinguish classes for certain names.  For example, symbol ‘$’ and ‘%’ are good 
indicators of class MONEY and PERCENTAGE respectively.  However, in biomedical 
domain, orthographic features are more likely to be served as indicators of unknown 
words, such as newly invented abbreviations.  For example, “IL-2” is in the training data, 
but “IL-12” is not.  Fortunately, we can guess that “IL-12” is similar to “IL-2” based on 
their orthographic features.  Therefore, orthographic features are intuitively helpful to 
identify new biomedical names. 
 
In our work, we manually designed orthographic features based on the characteristics of 
biomedical names.  Table 3.1 shows the list of orthographic features we designed by 
descending order of priority. 
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Fo Name Example Explanation 
Comma , comma 
Dot . dot 
LRB ( left round bracket 
RRB ) right round bracket 
LSB [ left squared bracket 
RSB ] right squared bracket 
RomanDigit II, IV Roman digit 
GreekLetter beta Greek letter 
StopWord in, at stop word 
ATCGseq AACAAAG nucleotide sequence 
OneDigit 5 one digit 
AllDigits 60 all digits 
DigitCommaDigit 1,25 digits + comma + digits 
DigitDotDigit 0.5 digits + dot + digits 
OneCap T single capital letter 
AllCaps CSF all capital letters 
CapLowAlpha All capital letter followed by lowercase letters 
CapMixAlpha IgM capital letter followed by mixture of cases 
LowMixAlpha kDa lowercase letter followed by mixture of cases 
AlphaDigitAlpha H2A letters + digits + letters 
AlphaDigit T4 letters + digits 
DigitAlphaDigit 6C2 digits + letters + digits 
DigitAlpha 19D digits + letters 
Table 3.1: Sorted list of orthographic features by descending order of priority 
 
From Table 3.1, we can find that the features such as GreekLetter, RomanDigit, ATCGseq 
and features dealing with mixed alphabetical letters and digits are specially designed for 
biomedical domain.  In fact, features dealing with mixed alphabetical letters and digits 
such as AlphaDgtAlpha, CapMixAlpha, etc. are beneficial for biomedical abbreviations.  
Moreover, features such as ATCG nucleotide sequence identify the similarity of the 
special biomedical notations according to their orthographical forms, e.g. AACAAAG, 
CTCAGGA, etc.  Besides these, some features such as comma, dot, StopWord and LSB, 
etc. are designed intuitively to provide information to detect the boundary of names.  
Especially, parentheses are often used to indicate the definition of abbreviation in 
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biomedical documents.  Intuitively, they are useful to identify abbreviations.  In Section 
4.3, we will explain how to use parentheses to deal with abbreviation in detail. 
 
3.2 Morphological Features (Fm) 
Morphological information, such as prefix and suffix, is considered as an important cue 
for terminology identification.  In our work, we use statistical method to get most frequent 
N prefixes and suffixes from training data as candidates.  Then, each of these candidates is 







## −=                              (4.1) 
In formula 4.1, #INi is the number of times that prefix or suffix i occurs within names; 
#OUTi is the number of times that prefix or suffix i occurs out of names; Ni is the total 
number of occurrence of prefix or suffix i. 
 
The formula assumes that the particular prefix or suffix, which is most likely inside 
biomedical names and least likely outside biomedical names, may be thought as a good 
evidence for recognition.  The candidates with Wt above a certain threshold (0.7 in 
experiment) are chosen.  In the next step, we calculated the frequency of each prefix or 
suffix in each biomedical name class, and group the prefixes or suffixes with similar 
distributions among name classes into one feature.  This is because prefixes or suffixes 
with similar distributions have similar contributions.  The grouping procedure reduced the 
total number of features and prevented the model from suffering from the data sparseness 
problem.  Table 3.2 shows some examples of the morphological features used in our work. 
 
 - 20 -
Chapter 3: Features 
Fm Name Prefix/Suffix Example 
sOOC ~cin actinomycin 
 ~mide Cycloheximide 
 ~zole Sulphamethoxazole 
sLPD ~lipid Phospholipids 
 ~rogen Estrogen 
 ~vitamin dihydroxyvitamin 
sCTP ~blast erythroblast 
 ~cyte thymocyte 
 ~phil eosinophil 
sPEPT ~peptide neuropeptide 
sMA ~ma hybridoma 
sVIR ~virus cytomegalovirus 
Table 3.2: Examples of morphological features 
 
From Table 3.2, we can find that the suffixes ~cin, ~mide, ~zole have been grouped into 
one feature sOOC because they all have the high frequency in the biomedical name class 
OTHER-ORGANIC-COMPOUND and relatively low frequencies in the other name 
classes. 
 
3.3 Part-of-Speech Features (Fpos) 
In the previous research of named entity recognition in newswire domain, part-of-speech 
(POS) feature was stated not useful.  Part-of-speech information mainly aims to identify 
boundaries of names.  In newswire domain, certain orthographic information such as 
capitalization is dominant in playing such a role, as we have already showed that nearly 
98% of words in newswire named entities are capitalized.  Thus, part-of-speech features 
may not help much and even degrade the performance in newswire domain [Zhou and Su 
2002].   
 
 - 21 -
Chapter 3: Features 
In biomedical domain, orthographic information is not strong enough for name 
identification, since many names are not capitalized.  Besides this, many biomedical 
names are descriptive and long, identifying the name boundaries is not a trivial task.  
Intuitively, names are more likely to occur within noun phrases than other phrases.  Part-
of-speech tags can provide the evidence of the noun phrase region based on the syntactic 
information of the words.  In our work, we will show that the part-of-speech feature is an 
important feature in biomedical name recognition. 
   
However, in previous related work, [Kazama et al. 2002] made use of part-of-speech 
information and concluded that it could only slightly improve the performance.  In 
[Collier et al. 2000], [Nobata et al. 2000] and [Takeuchi and Collier. 2002], part-of-speech 
information was not incorporated in their models.  The probable reason explained by them 
was that the part-of-speech taggers they used were trained on the newswire documents.  
Thus, the part-of-speech tags may not be accurate enough in the biomedical domain.  On 
the whole, part-of-speech information hasn’t been well used in previous related work of 
biomedical name recognition. 
 
To demonstrate the effect of adaptation on part-of-speech tagging, we trained an HMM-
based part-of-speech tagger for biomedical domain using GENIA corpus V2.1 (670 
abstracts, 123K words).  We use 590 abstracts as the training set and the rest 80 abstracts 
as the test set.  As for comparison, we also trained a part-of-speech tagger on the PENN 
TreeBank (2500 Wall Street Journal articles, 1M words) and evaluated on the same 80 
abstracts of GENIA corpus.  The results are shown in Table 3.3. 
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Training set Test set Precision 
590 GENIA abstracts 97.4 
2500 WSJ articles 80 GENIA abstracts 85.1 
Table 3.3: Performance comparison between part-of-speech taggers using training 
data in different domains 
 
From Table 3.3, we can find that the part-of-speech tagger trained in the biomedical 
domain performs much better on the test set than that trained on WSJ documents.  This is 
consistent with the earlier explanation for why part-of-speech features are not so useful in 
biomedical name recognition [Nobata et al. 2000], [Takeuchi and Collier 2002]. 
 
In Chapter 5, we will show the effect of different part-of-speech taggers trained with 
different training data on the biomedical name recognition.  
 
 
3.4 Semantic Trigger Features 
We designed semantic trigger features in order to provide indications of certain 
biomedical name classes based on the semantic information of some trigger words.  
Trigger words are key words inside or outside of names, which have strong indication for 
name recognition.  Initially, we collected two types of semantic triggers: head noun 
triggers and special verb triggers. 
 
3.4.1 Head Noun Triggers (Fhnt) 
Head noun means the main noun or noun phrase of some compound words, which 
describes the function or property of these words, e.g. “B cells” is the head noun for the 
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name “activated human B cells”.  Compared with the other words in the biomedical names, 
head noun is a much more decisive factor for distinguishing the classes.  For instances, 
<OtherName>IFN-gamma treatment</OtherName> 
<DNA>IFN-gamma activation sequence</DNA> 
Both instances above begin with the “IFN-gamma” with only a difference in head nouns, 
“treatment” and “sequence”.  These two biomedical names belong to two different classes: 
OTHER-NAME and DNA.  This example implies that no matter how many similar 
expressions are within the names, the classes of the names are normally determined by the 
head nouns which often indicate the functions of the names.  [Nobata et al. 1999] also 
argued that head nouns in noun phrases can provide significant clues about the class and 
gave head noun a higher weight in their statistical model.  
Name class Unigram Bi-grams head noun 
 kinase binding protein 
 interleukin activator protein 
PROTEIN interferon gene product 
 ligand cell receptor 
 … … 
 lymphocyte blast cell 
 astrocyte blood lymphocyte 
CELL TYPE fibroblast peripheral monocyte 
 eosinophil killer cell 
 … … 
 DNA X chromosome 
 cDNA alpha promoter 
DNA chromosome binding motif 
 breakpoint promoter element 
 … … 
 virus recombinant virus 
 provirus lymphotropic herpesvirus 
VIRUS cytomegalovirus virus particles 
 adenovirus immunodeficiency virus 
 … … 
Table 3.4: Examples of auto-generated unigram and bi-grams head noun 
triggers for 4 classes 
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In our work, head noun features were retrieved automatically, which made our model easy 
to be adapted to a new domain.  We extracted unigram and bi-grams of head nouns 
automatically from training data and rank them by frequency.  For each name class, we 
selected 60% top ranked head nouns for both unigram and bi-grams head noun trigger lists.  
A sample list of auto-generated head nouns for certain name classes is shown in Table 3.4.  
In the future work, head nouns may also be extracted from some public resources for 
further enhancement. 
 
3.4.2 Special Verb Triggers (Fsvt) 
Besides collecting the trigger words inside biomedical names, such as head noun triggers, 
we can also make use of trigger words from the local context of names.  Recently, some 
frequently occurred verbs in MEDLINE have been proven useful for extracting the 
interaction between biomedical entities, e.g. the protein-protein interactions [Thomas et al. 
2000], [Sekimizu et al. 1998].  In biomedical name recognition, we have the intuition that 
particular verbs may also provide information for boundary and class of biomedical names.  
For instance, the verb “bind” often indicates interaction between proteins.   
In our work, we selected 20 most frequent verbs which occur adjacent to biomedical 
names from training data automatically as the special verb trigger features, which are 
shown in Table 3.5. 
Special Verb Trigger 
activate associate bind block clone 
demonstrate express identify increase induce 
inhibit investigate involve isolate mediate 
observe reduce regulate reveal stimulate 
Table 3.5: 20 top frequent special verb triggers 
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4.1 Hidden Markov Model 
Hidden Markov Model (HMM) is a statistical method.  In the past fifteen year, HMM has 
been successfully used in a wide range of applications, such as speech recognition and 
natural language processing.  A HMM is a model where a sequence of outputs is 
generated in addition to the Markov state sequence.  It is a latent variable model in the 
sense that only the output sequence is observed while the state sequence remains "hidden". 
 
In name entity recognition, the input word sequence, (e.g. sentence), can be regarded as 
the observation sequence and the output tag sequence is the optimal state sequence 
corresponding to the words.   
 
 
4.2 Hidden Markov Model-based Name Recognizer 
In our work, the name recognizer is adapted from the previous work of the HMM-based 
Named Entity Recognizer on MUC [Zhou and Su 2002].  The core technique is a Hidden 
Markov Model as follows. 
 
The name recognizer tries to find the most likely tag sequenceT t  for a given 
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token  is defined as , where  is the word and  is the feature sets 
corresponding to the word .  The feature sets have been introduced in Chapter 3 in detail.  
In tag sequenceT , each tag t is structural and consists of three parts: boundary category, 
name class and feature set.  The boundary category indicates whether the word itself is a 
name, or the word is at the beginning, in the middle, or at the end of a name.  The name 
class consists of a NOT-NAME class and a predefined set of name classes.   The feature 
set is added in order to represent more accurate models. [Zhou and Su 2002] 
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The second term of the right-hand side of equation (4.1) is the mutual information 
between T  andO .  We assume mutual information independence: n1
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Applying equation (4.2) to equation (4.1), we have: 
1 1
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The first term in equation (4.3) can be computed by applying chain rules.  Each tag is 
assumed to be probabilistically dependent on the N-1 previous tags in N-gram modeling.  
The second term is the sum of log probabilities of all the tag instances.  The third term can 
be ideally estimated by the forward-backward algorithm recursively [Rabiner 1998].  As 
we designed a rich feature set in HMM, we will encounter the data sparseness problem.  
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An alternative back-off modeling approach by means of constraint relaxation was applied 
in our model [Zhou and Su 2002].  It enables the decoding process effectively find a near 
optimal frequently occurred pattern entry in determining the tag probability distribution of 
current word. 
 
The Viterbi algorithm [Viterbi 1967] is implemented to find the most likely tag sequence 
in the state space of the possible tag distribution based on the state transition probabilities.  
Meanwhile, some constraints on the boundary category and entity category between two 
consecutive tags are applied to filter the invalid name tags. 
 
4.3 Abbreviation Recognition 
In Chapter 2, we have analyzed the characteristics of abbreviations in the biomedical 
domain.  We find that it is difficult to recognize biomedical abbreviations in documents.  
Therefore, specific methods should be developed for recognizing them.  Since most 
abbreviations have special orthographic formations, it is relatively easy to identify their 
locations.  However, it is difficult to determine whether they are biomedical abbreviations 
or other abbreviations.  If they are biomedical abbreviations, it is still a real challenge to 
determine which name classes they belong to. 
 
In our work, we introduce a method to recognize abbreviations by mapping them to their 
full forms. This approach is based on the assumption that full forms are easier to be 
classified than abbreviations.  In most cases, this assumption is valid because the full 
forms have more features than their abbreviations for classification.  Therefore, if the 
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mapping is successful, the classes of abbreviations can be determined from the classes of 
their full forms, which are more likely to be correct.  In a document-level point of view, if 
we can map the abbreviations to their full forms in the current document, the recognized 
abbreviations will be helpful for classifying the same forthcoming abbreviation throughout 
the document using the name alias feature, as in [Zhou and Su 2002]. 
 
In biomedical documents, abbreviations are often defined first before they are used.  
[Schwartz and Hearst 2002] found that abbreviations and their full forms occur together 
with a pair of parentheses in most cases.  Normally, there are two patterns: 
1. full form (abbreviation) 
2. abbreviation (full form) 
Most occurrences of abbreviations conform to the first pattern.  If there are more than two 
words in the parenthesis, the second pattern is assumed [Schwartz and Hearst 2002].   
 
In our name recognition model, we specially treat parentheses since they can be both 
useful and confusing.  On one hand, parentheses strongly indicate location of 
abbreviations and help to map abbreviations to their full forms.  On the other hand, 
parentheses will sometimes confuse the recognition model because they make the 
construction of names more complex.  Normally, an abbreviation follows its full form, 
such as “<Protein>T cell factor</Protein> (<Protein>TCF</Protein>)”.  However, 
since biomedical names can be cascaded, an abbreviation may be embedded in a longer 
name, for example, “<DNA>chloramphenicol acetyltransferase (CAT) gene</DNA>”.   
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Based on the characteristics of the parentheses, we design our biomedical abbreviation 
recognition method which takes advantage of the usefulness as well as reduces the 
confusion of parentheses.  We reduce the complexity of sentence by extracting out all 
parentheses pairs in the first step.  Therefore, parentheses will not affect the name 
recognition in that sentence.  After the recognition, all parentheses items are restored back 
to the sentence.  Now, we can take advantage of the usefulness of the parentheses to 
recognize abbreviations by analyzing the relationship between full forms and 
abbreviations.  The algorithm of our biomedical abbreviation recognition method is 
presented in Figure 4.1. 
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For each sentence Si in the document{ 
if exist parenthesis{ 
judge the case of { 
“full form (abbr.)”; 
“abbr. (full form)”; 
} 
store the abbr. A and position Pa  to a list; 
record the parenthesis position Pp; 
remove A and parenthesis from sentence; 
apply HMM-based name recognizer to Si; 
restore A and parenthesis into Pa, Pp; 
if Pp within an recognized name E with the class CE 
parenthesis is included in E; 
else{ 
parenthesis is not included; 
classify A to CE; 
classify A in the rest part of document to CE; 
} 
} 
else apply HMM-based name recognizer to Si; 
} 
Figure 4.1: Biomedical abbreviation recognition algorithm 
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4.4 Cascaded Name Recognition 
As mentioned in Section 2.5, cascaded-annotation is a special problem in biomedical 
name recognition.  For instance, “<CELL-LINE><VIRUS>HTLV-I</VIRUS>-infected cord 
blood lymphocytes</CELL-LINE>” is a name of class CELL-LINE and it embeds a virus 
name “HTLV-I”.  In cascaded name recognition, we shall recognize both the embedded 
name and the longest name.  However, in real applications, people care more about names 
to the longest extent for two reasons.  First, names to the longest extent are more likely to 
be the subjects that people want to study.  Second, it keeps all information about 
embedded names.  Therefore, whether keeping the embedded names or not depends on the 
user requirements under different circumstances.  In our work, we tried two approaches: 
post-processing rule-based approach and HMM-based approach.  
 
4.4.1 Post-Processing Rule-based Approach 
The post-processing rule-based approach aims to recognize names to the longest extent.  
For a one-pass recognition procedure, it is not guaranteed that the longest names will be 
recognized.  Instead, embedded names are sometimes recognized.  For example: 
… cocultured with a bone marrow-derived stromal cell line revealed …
                                                    tissue                                      cell_line 
 
In the above case, the embedded tissue name “bone marrow” is recognized, while we 
prefer to recognize the name of the cell line.  The possible reason for this kind of cases is 
that embedded name can be individual name itself, and it contains features for itself to be 
recognized.  The word “marrow” is a head noun for name class TISSUE, thus “bone 
marrow” is likely to be recognized as a tissue name.  Although “cell line” is the head 
noun for name class CELL-LINE, the context is too long to be captured. 
 - 32 -
Chapter 4: Methodology 
 
We proposed a post-processing rules approach to deal with these cases caused by 
cascaded-annotation.  The main idea is that we try to develop a set of patterns which help 
recognize names to the longest extent based on embedded ones.  From GENIA corpus 
annotation, we collected four basic patterns of cascaded names (Table 4.1).  In addition, 
we also extend the patterns by combining the basic ones iteratively. 
Basic patterns 
  <NAME’> = <NAME> [head nouns] 
  <NAME’> = [modifier] <NAME> 
  <NAME’> = <NAME1> <NAME2> 
  <NAME’> = <NAME1> [words] <NAME2> 
Extended patterns 
  <NAME’> = [modifier] <NAME> [head nouns] 
  <NAME’> = [modifier] <NAME1> <NAME2> 
  <NAME’> = <NAME1> <NAME2> [head nouns] 
  … 
Table 4.1: Patterns of cascaded names 
 
Based on these patterns, we can construct a rule set automatically from the training corpus.  
Table 4.2 shows an example list of instances of the post-processing rules which were 
generated from the training data of GENIA corpus. 
Rule instance <DNA> = <PROTEIN> binding site 
From pattern  <NAME’> = <NAME> [head nouns] 
Example A Myc-associated zinc finger protein binding site is one of … 
 
Rule instance <PROTEIN> = <VIRUS> <PROTEIN> 
From pattern <NAME’> = <NAME1> <NAME2> 
Example Nevertheless, the simian EBV LMP1s retain most functions in … 
 
Rule instance <CELL-TYPE> = human <CELL-TYPE> 
From pattern <NAME’> = [modifier] <NAME> 
Example … suggests that human NK cells provide an effective … 
 
Rule instance <CELL-TYPE> = <VIRUS> -infected <CELL-TYPE> 
From pattern <NAME’> = <NAME1> [words] <NAME2> 
Example … p24 production by HIV –infected human macrophages when … 
Table 4.2: Examples of post-processing rules for cascaded name recognition 
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After name recognition by our HMM-based recognizer, we get an initial result.  Then, we 
develop a post-processing procedure by applying the above rules to the initial result.  For 
example, given the initial result “a <PROTEIN>Myc-associated zinc finger 
protein</PROTEIN> binding site is one of …”, the post-processing procedure finds that it 
matches the rule “<DNA> = <PROTEIN> binding site”.  After post-processing, the final 
result will change to “a <DNA>Myc-associated zinc finger protein binding site</DNA> is 
one of …”.  Therefore, we recognized the name to the longest extent.  In addition, the 
post-processing rules are applied iteratively until no new match can be found.  For 
example, given the initial result “… <AMINO-ACID-MONOMER>tyrosine</AMINO-ACID-
MONOMER> kinase inhibitor …”, the post-processing procedure finds that it matches the 
rule “<PROTEIN> = <AMINO-ACID-MONOMER> kinase” and changes it to “… 
<PROTEIN>tyrosine kinase</PROTEIN> inhibitor …” in the first iteration.  In the next 
iteration, the post-processing procedure finds that the intermediate result matches the rule 
“<OTHER-ORGANIC-COMPOUND> = <PROTEIN> inhibitor” and updates it again.  Since no 
more matches will occur in the following iterations, the final result is “… <OTHER-
ORGANIC-COMPOUND>tyrosine kinase inhibitor</OTHER-ORGANIC-COMPOUND > …”. 
 
Experimental result showed that post-processing rules approach is an effective approach.  
Detailed results will be shown in Chapter 5. 
 
4.4.2 HMM-based Iterative Recognition Approach 
Besides post-processing rules approach, we also proposed an HMM-based iterative 
recognition approach to recognize names with cascaded-annotation.  The HMM-based 
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approach tries to start recognition from the shortest embedded name and extends to longer 
name iteratively.  
We train two HMM models in this approach.  First model is the model of our original 
name recognizer, which is mainly for the recognition of the short embedded names.  
Besides this, we also train another HMM model for iterative extension for longer names 
by using cascaded-annotation in the training corpus.  For training this iterative model, we 
make use of the cascaded-annotations and transform them into a new training data set.  
For example: 
 
<DNA><PROTEIN>Myc-associated zinc finger protein<PROTEIN> binding site</DNA>
 
<DNA> [PROTEIN] binding site</DNA> 
We substitute a class-representing token “[PROTEIN]” for the embedded name of protein.  
After this transformation, all cascaded-annotated names in the training data become non-
cascaded.  We can train an HMM model on this training data as an iterative recognition 
model.  Intuitively, the HMM model can capture local context information more easily 
than long context information.  Some long cascaded names are difficult to be recognized 
in one pass as shown in the previous section.  We hope that long cascaded names can be 
recognized by two or more iterations if they are missed in the first pass.  Therefore, we 
can use the same HMM method and do not need any post-processing step.  One limitation 
of the approach may be that the following iterations rely on the first recognition pass.  In 
an ideal situation, if the performance is high in the first pass, the longer names are likely 
to be recognized in the following iterations.  In our work, we are concerning about the 
performance of the longest names, the performance evaluation in the experiment is 
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conducted on them.  The algorithm of the HMM-based iterative recognition approach is 
shown in Figure 4.2.   
for each sentence Si in the document{ 
apply the first pass HMM name recognition model to Si ; 
for each recognized name Nj { 
record Nj to a stored-list; 
substitute a class-label token CT(Nj) for Nj in Si ; 
} 
loop until no name can be recognized in Si{ 
apply the iterative recognition HMM model to Si ; 
for each Nj in the stored-list { 
if CT(Ni) is embedded in newly recognized name N’k { 
restore content of Nj to original position CT(Nj) in Si ; 
remove Nj from the stored-list; 
} 
} 
for each newly recognized name N’k { 
record N’k to a stored-list; 




Figure 4.2: Algorithm of HMM-based iterative recognition approach for cascaded name 
recognition 
 
In addition, we can also generalize the model to a recursive process which can be used to 
recognize all levels of the cascaded-names, i.e. not only the longest names but also the 
embedded ones.   The algorithm for this generalized method is shown in Figure 4.3. 
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for each sentence Si in the document{ 
apply first pass HMM name recognition model to Si 
for each recognized name Nj { 
record Nj to a stored-list; 
substitute a class-label token CT(Nj) for Nj in Si 
} 
recursive-recognize-cascaded-name(Si); 
for each Nj in the stored-list { 




function recursive-recognize-cascaded-name(sentence S){ 
apply the iterative recognition HMM model to S ; 
if no name is recognized then return ; 
for each recognized name Ni { 
record Ni to a local stored-list; 
substitute a class-label token CT(Ni) for Ni in S ; 
} 
recursive-recognize-cascaded-name(S); 
for each Ni in the stored-list { 
restore Ni to original position CT(Ni) in S ; 
} 
} 
Figure 4.3: Algorithm of a generalized recursive method for all-level cascaded name recognition 
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4.5 Work Flow of Biomedical Name Recognition 
In the whole process of biomedical name recognition, the core HMM-based name 
recognizer module is collaborated with other modules, including a preprocess module, a 
part-of-speech tagger, and a cascaded names recognition module.  The work flow of the 









HMM-based Name Recognition 
including abbreviation recognition
Cascaded Name Recognition Cascaded Name Recognition 
by post-processing rules by HMM-based iterative recognition 
Output Output 
(with recognized names) (with recognized names) 
Figure 4.4: Flowchart of biomedical name recognition 
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5.1 Data set 
Currently, GENIA corpus1 is the largest annotated corpus in molecular biology domain 
available to public [Ohta et al. 2002].  In our experiment, three versions are used, which 
are V1.1, V2.1 and V3.02.  The annotation of biomedical name is based on the GENIA 
ontology [Appendix].  In our task, we try to recognize 22 distinct name classes2 defined in 
the GENIA ontology, including MULTI-CELL, MONO-CELL, VIRUS, BODY-PART, TISSUE, 
CELL-TYPE, CELL-COMPONENT, CELL-LINE, OTHER-ARTIFICIAL-SOURCE, PROTEIN, 
PEPTIDE, AMINO-ACID-MONOMER, DNA, RNA, POLYNUCLETOTIDE, NUCLEOTIDE, 
LIPID, CARBOHYDRATE, OTHER-ORGANIC-COMPOUND, INORGANIC, ATOM and OTHER.   
5.1.1 GENIA corpus V1.1 
It contains 670 MEDLINE abstracts.  Since a lot of previous related works were based on 
this version, we use it to compare our result with others’ works. 
 
5.1.2 GENIA corpus V2.1 
It contains the same 670 abstracts as V1.1 with additional part-of-speech tagging.  We use 
this version of corpus to adapt the part-of-speech tagger to the biomedical domain and 
make evaluations. 
                                                 
1 Downloaded from http://www-tsujii.is.s.u-tokyo.ac.jp/GENIA/ 
2 In previous work on GENIA V1.1, there are 23 name classes due to inconsistent annotations of class 
ORGANISM.  According to GENIA ontology, ORGANISM is not a name class in V3.02.  We do not 
differentiate the subclasses of PROTEIN, DNA and RNA. 
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5.1.3 GENIA corpus V3.02 
It contains 2000 MEDLINE abstracts, which is a superset of GENIA corpus V1.1.  We use 
this version of corpus to evaluate our system more consistently and to find out the effect 
of training data size. 
 
5.2 Experiments for Biomedical Name Recognition 
5.2.1 Experiment Settings 
We conducted experiments for biomedical name recognition both on GENIA corpus V1.1 
and V3.02.  For GENIA corpus V1.1, we split the corpus into a training set of 590 
abstracts and a test set of 80 abstracts.  We keep the same training/test ratio as [Kazama et 
al. 2002] in order to make comparisons.  For GENIA corpus V3.02, 2000 abstracts were 
split to a training set of 1920 abstracts and a test set of 80 abstracts.  The test set in this 
setting is the same as the test set for GENIA corpus V1.1 in order to evaluate the impact 
of training size.  As a summary, the settings for biomedical name recognition are shown in 
Table 5.1. 
 V1.1 V3.02 
Training set 590 abstracts 1920 abstracts 
Test set 80 abstracts 
Table 5.1: Experiment settings for biomedical name recognition 
on GENIA corpus V1.1 and V3.02 
 
5.2.2 Experiment Results 
The performance of our model is evaluated using “precision/recall/f-measure”, in which 
“precision” is calculated as the ratio of the number of correctly found names to the total 
number of names found by our model; “recall” is calculated as the ratio of the number of 
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correctly found names to the number of true names; and “f-measure” is defined by 
Formula 5.1. 
2 precision recallf measure
precision recall
× ×− = +    (5.1) 
 
The experiment results on the overall performance of the three settings and the result of 
[Kazama et al. 2002] are shown respectively in Table 5.2. 
 Precision Recall F-measure 
 Our model on V3.02 67.7 65.3 66.5 
Our model on V1.1 63.8 61.3 62.5 
[Kazama et al. 2002] on V1.1 56.2 52.8 54.4 
Table 5.2: Overall performance of biomedical name recognition on GENIA corpus 
V3.02 and V1.1, comparing to [Kazama et al. 2002] on GENIA corpus V1.1. 
 
On V1.1, Our system (62.5 F-measure) outperforms [Kazama et al. 2002] (54.4 F-measure) 
by 8.1 F-measure.  It probably benefits from the various evidential features and the 
effective methods we proposed.  Furthermore, as expected, the performance achieved 
(66.5 F-measure) on V3.02 is better than that on V1.1 (62.5 F-measure), which indicate 
that training data size matters.  In the later section 5.2.5, we will show a detailed 
experiment result on the effect of training data size.    
 
Besides the overall performance, we also evaluated performances of all the name classes, 
which are shown in Table 5.3.  From Table 5.3, we can find that performance varies a lot 
among different name classes.  It is probably due to two reasons.  First, different name 
classes have different difficulties for name recognition.  For example, the name class 
BODY-PART is one of the easiest classes since the number of instances for body part is 
limited.  Second, we can find that the numbers of training and test instances are not evenly 
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distributed among all the name classes.  Some minor name classes, such as 
NUCLEOTIDE, ATOM, INORGANIC, CARBOHYDRATE and etc, lack enough training or 
test data to achieve acceptable performances. 
Name class # Train Instance 
# Test 
Instance P R F 
BODY-PART 378 16 73.68 87.50 80.00 
CELL-TYPE 6219 212 78.18 81.13 79.63 
LIPID 1617 78 74.68 75.64 75.16 
MULTICELL 1516 99 68.47 76.77 72.38 
PROTEIN 24493 790 71.88 72.15 72.01 
OTHER-ORGANIC-COMPOUND 3487 106 74.00 69.81 71.84 
CELL-LINE 3658 134 68.85 62.69 65.62 
AMINO-ACID-MONOMER 361 25 64.00 66.66 65.30 
DNA 8376 474 66.90 60.13 63.33 
CELL-COMPONENT 602 33 59.46 66.67 62.86 
POLYNUCLEOTIDE 234 15 58.82 66.67 62.50 
OTHER-NAME 19131 702 62.17 61.11 61.64 
RNA 698 69 82.50 47.83 60.55 
VIRUS 1009 63 75.61 50.17 60.32 
TISSUE 625 15 66.67 53.33 59.26 
MONO-CELL 177 2 50.00 50.00 50.00 
NUCLEOTIDE 126 6 100.00 16.67 28.57 
PEPTIDE 398 9 14.29 11.11 12.50 
ATOM 156 3 0 0 0 
INORGANIC 210 1 0 0 0 
CARBOHYDRATE 69 0 0 0 0 
OTHER-ARTIFICIAL-SOURCE 199 0 0 0 0 




5.2.3 Effectiveness of Feature Sets 
In order to evaluate the contribution of each feature set, we conducted experiments on 
various combinations of features on V3.02.  The results are shown in Table 5.4. 
 
From Table 5.4, we analyze the contribution of each feature in the following part: 
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1) Based on orthographic feature (Fo), our system achieves a basic level performance of 
29.4 F-measure.  In MUC-7 task, performance can reach 77.6 F-measure by using 
orthographic feature only [Zhou and Su 2002].  It suggests that in biomedical domain 
orthographic feature is not so informative, which is consistent with what we analyzed in 
the Chapter 3. 
Fo Fm Fpos Fhnt Fsvt Precision Recall F-measure 
√     41.8 21.8 28.7 
√ √    44.4 24.3 31.4 
√  √   55.7 49.4 52.3 
√   √  55.9 44.9 49.8 
√ √ √   58.0 51.3 54.5 
√ √  √  55.8 44.8 49.7 
√  √ √  61.9 61.5 61.7 
√ √ √ √  61.9 61.7 61.8 
√ √ √ √ √ 60.6 59.3 60.0 
Table 5.4: Experimental results for biomedical name entity recognition by using 
different combinations of features. 
 
2) Morphological feature (Fm) led to positive effect by +2.7 F-measure improvement 
based on Fo and +2.2 F-measure improvement based on Fo+Fpos.  However, it cannot make 
improvement based on Fo+Fhnt and can only slightly improve the Recall by +0.2 based on 
Fo+Fpos+ Fhnt.  The probable reason is that Fm and Fhnt provide some overlapping 
information.  The evidences included in Fm probably can also be captured by Fhnt.  More-
over, the evidences captured by Fhnt are more accurate than that captured by Fm.  The 
contribution made by Fm may come from where there is no indication of Fhnt. 
 
3) Part-of-speech feature (Fpos) is proved very beneficial as it makes significant 
improvement on F-measure (+23.6 based on Fo; +23.1 based on Fo+Fm; +11.9 based on 
Fo+Fhnt; +12.1 based on Fo+Fm+Fhnt).  This is greatly benefited from the adaptation of the 
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part-of-speech tagger to the biomedical domain.  In order to show the effect of the 
adaptation of part-of-speech, we made further experiments by using part-of-speech 
features assigned by part-of-taggers trained on different corpus.  Table 5.5 shows the 
results of the experiments. 
Precision of part-of-speech tagger  
No POS 71.31 83.49 85.10 97.17 97.40 
Precision 62.2 64.2 65.6 66.3 66.9 67.7 
Recall 48.2 55.7 62.7 63.5 64.1 65.3 
F-meaure 54.3 59.6 64.1 64.9 65.5 66.5 
Table 5.5: Effect of adaptation of POS tagger on biomedical name recognition 
(The POS tagger with the precision 85.10 is trained on 2500 WSJ articles; The POS tagger 
with precision 97.40 is trained on GENIA corpus V2.1; The POS tagger with precision 
97.17 is trained on a combined training set of WSJ articles and GENIA corpus V2.1; The 
other POS taggers are trained on subsets of 2500 WSJ articles.  The biomedical name 
recognition is based on Fo+Fm+Fpos+Fhnt and abbreviation recognition and post-
processing-rule cascaded name recognition method) 
  
4) Head noun trigger feature (Fhnt) has also been proved very useful.  It greatly improves 
the F-measure (+21.1 based on Fo; +18.3 based on Fo+Fm; +9.4 based on Fo+Fpos; +7.3 








Precision 67.7 67.3 67 66.9 67 66.7
Recall 65.3 64.9 64.6 64.6 64.6 64.5
F-measure 66.5 66.1 65.8 65.7 65.8 65.6
No verbs 20 verbs 50 verbs 100 verbs 150 verbs 200 verbs
 
Figure 5.1: Effect of using special verb triggers on biomedical name recognition 
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5) Out of our expectation, the special verb trigger feature (Fsvt) decreases both precision 
and recall and degrades the F-measure (-1.8 based on Fo+ Fm+Fpos+ Fhnt).  Since we just 
used 20 special verbs and did not consider abbreviation and cascaded recognition methods 
in this evaluation, we conducted further experiments using all features, abbreviation 
recognition method and post-processing rule approach for cascaded name recognition to 
show the effect of special verb trigger size on the whole system.  Figure 5.1 shows the 
result table and chart of the performances by using different number of special verbs as 
Fsvt. 
 
From the Figure 5.1, we find that the more special verbs we use, the worse the 
performance is.  It indicates that special verb triggers are not helpful in our model.  One 
possible reason is that the present and past participles of some special verbs often play the 
adjective-like roles inside biomedical names, such as “IL10-inhibited lymphocytes”.  
Another possible reason is that the function of special verbs is very unpredictable in the 
corpus even the verbs are very informative in the context.  For example: 
 
<CELLCOMPONENT>B95-8 cytosol</CELLCOMPONENT> inhibited specific binding … 
… nuclear activity in <CELLLINE>IL-10 -inhibited lymphocytes</CELLLINE> … 
… and TLCK inhibited <OTHERNAME>LPS induction</OTHERNAME> of … 
 
5.2.4 Effectiveness of Methods for Abbreviation and Cascaded Names 
In order to evaluate our proposed methods for abbreviation and cascaded name 
recognition, we made further experiments based on the four feature sets which led to the 
best performance as shown in the previous section.  The results are summarized in Table 
5.6. 
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V3.02 Precision Recall F-measure 
Fo+Fm+Fpos+Fhnt (4F) 61.9 61.7 61.8 
4F+abbreviation recognition 63.4 62.7 63.0 
4F+abbr.+post-processing rule-based app. 67.7 65.3 66.5 
4F+abbr.+ HMM-based iterative recognition app. 65.5 63.0 64.2 
Table 5.6: Effectiveness of abbreviation recognition method and two cascaded name 
recognition methods 
 
First, we evaluated the contribution of abbreviation recognition method.  The result 
showed that the method led to an improvement on F-measure by 1.2 based on the best 
combination of features Fo+Fm+Fpos+Fhnt (4F).  The reason why the improvement was not 
so significant is that our abbreviation recognition method mainly relies on the recognition 
of its full form.  Once the full form is wrongly recognized, all abbreviations can be wrong 
altogether.  However, the principle of the method is reasonable and the result is positive.  
Our abbreviation recognition method provides an effective and reasonable solution when 
domain-specific abbreviation dictionaries are not available. 
 
Furthermore, we evaluated the two approaches for recognition of cascaded names that we 
proposed in section 4.4.  Using post-processing rule-based approach, we got a significant 
improvement by 3.5 F-measure.  Another approach, the HMM-based iterative recognition 
approach, also led to a positive effect of +1.2 F-measure.  We can find that the post-
processing rule-based approach outperforms the HMM-based iterative recognition 
approach.  It is probably because the HMM-based iterative recognition approach does not 
have enough training data on the cascaded name phenomena to get a reliable performance.  
However, the HMM-based iterative recognition approach is more general and can be 
enhanced when we have enough training instances for the cascaded name phenomena.  
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5.2.5 Effect of Training Data Size 
One important issue is about the effect of different training data size.  Figure 5.2 shows 
the learning curve of our name recognition model with different training data size.  From 
Figure 5.2, we can find our system still has some room for improvement with the larger 
training data set.  This is probably because our HMM model can better capture local 
context dependence and better resolve the sparseness problem.  However, although it is 
always true that more training data may lead to better performance, the more training data 
than about 200K words will not help much.  Figure 5.2 shows nearly 200K words of 
training data achieve the performance of 61.4 F-measure while adding to 450K words 
slightly increases the performance.  Therefore, in order to achieve reliable performance, 






0 50 100 150 200 250 300 350 400 450
Training Data Size (K Words)
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Figure 5.2: Effect of training data size for biomedical name recognition 
 
 
5.3 Error Analysis 
We randomly collected 100 error instances from the result of biomedical name recognition 
and produced a statistics on different types of errors.  According to our analysis, we sort 
the error instances into six types, including false positives, false negatives (miss), 
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misclassifications, modifier-caused errors, cascaded-annotation-caused errors and none-
of-the-above.  Table 5.7 shows the statistics table of the error samples.  In the following 
section, each type of error will be analyzed in details. 
 
Error Type # of instance 
False Positive 17 
False Negative (Miss) 33 
Misclassification 18 
Modifier-caused Error 14 
Cascaded-annotation-caused Error 14 
Miscellaneous Error 4 
TOTAL 100 
Table 5.7: Statistics of error types for biomedical name recognition by 
sampling 100 error instances 
 
5.3.1 False Positive 
False positive includes all wrongly recognized names that are not in the annotated 
evaluation data.  There are 17 instances out of the 100 samples.  This type of errors 
happens mostly in the name class OTHER-NAME (10/17), which is probably because 
there are many inconsistent annotations in the GENIA corpus and inconsistency is the 
most serious in name class OTHER-NAME.   However, among all the 17 error instances, 
we find that 11 instances are quite acceptable.  We say these instances are acceptable 
because we can find similar annotations in the corpus, which means inconsistency exists 
in annotations of the GENIA corpus.  For example, in one sentence, our model recognized 
a false positive instance of the name “lymphocyte activation” as a name of class OTHER-
NAME, while we can find that there are many “lymphocyte activation” annotated as a 
name of class OTHER-NAME in other places of the corpus.  Therefore, this error is due to 
annotation error and should be regarded as acceptable.     
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5.3.2 False Negative 
False negative errors account for the instances missed by our recognition model.  From the 
statistics, we find one third of the errors belong to false negative errors (33/100).  We find 
that the names missed by our model are relatively short and some of them are general 
nouns.  For example, we missed the name “expression” in “determining the patterns of 
<OTHERNAME>expression</OTHERNAME>.  “Expression” is a very general word in text.  
Most of the single word “expression” is not annotated as a name itself.  We regard such 
false negatives as acceptable instances.  We find that 10 out of the 33 instances are 
acceptable.     
 
5.3.3 Misclassification 
Misclassification accounts for right boundary detection but wrong class assignment.  We 
find that names in some classes are sense ambiguous.  In the corpus, one name can belong 
to two classes.  From the statistics, 18 error instances are misclassification errors.  Among 
them, 6 instances are related to the class DNA and 6 instances are related to the class 
CELL-LINE and the class CELL-TYPE.  We find only 2 instances are acceptable due to 
wrong annotation in the corpus.  All other instances are unacceptable. 
 
5.3.4 Modifier-caused Error 
Modifier-caused error accounts for correct right boundary detection, correct class 
assignment, but wrong identification on modifier.  This type error is mainly introduced by 
the inconsistent annotations on modifiers in the corpus, as shown in Figure 5.3.  Basically, 
 - 49 -
Chapter 5: Experimentation 
modifier-caused errors are less serious, since the class and the major part of the names are 
correct.  Among 14 instances, we find that 12 of them are acceptable. 
  Figure 5.3: Modifier annotation inconsistency in GENIA corpus 
 
 
5.3.5 Cascaded-annotation-caused Error 
Cascaded-annotation-caused error accounts for the error caused by the cascaded name 
phenomenon.  For example, the system recognizes the embedded name but not the name 
to the longest extent.  Although we have proposed two methods for solving this problem, 
the inconsistency in the corpus can still affect the recognition of certain cascaded names.  
According to the statistics, 18 instances belong to this category.  The criteria for 
acceptable error in this category can be different based on different understanding of 
usefulness of the error names.  We may assert that the error is acceptable if the embedded 
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name is correctly recognized.  Based on this criterion, we find that 11 of the 18 instances 
are acceptable. 
 
5.3.6 Miscellaneous Error 
This category includes all error instances that do not belong to any of the above categories.  
There are only 4 instances out of all the samples.  None of them is acceptable. 
 
5.3.7 Summary of Error Analysis 
From the error analysis, we find that about 46% (46/100) of the errors are acceptable.  It 
means we can reach an acceptable F-measure at about 81~82.  If we have more consistent 
annotation and other available resources such as dictionary, it is available for further 
performance improvement. 
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The research work presented in this thesis proposes and explores a machine learning 
method for biomedical name recognition.  Based on detailed analysis of special 
characteristics in biomedical names, a rich set of features including orthographic, 
morphologic, part-of-speech and semantic trigger features are proposed.  All these features 
are integrated effectively via a HMM model with back-off modeling.  In addition, we also 
present an abbreviation recognition method and two effective cascaded name recognition 
methods in order to cope with the special phenomena in biomedical names.  To our best 
knowledge, our work is the first detailed research work concerning about the cascaded 
name phenomenon in biomedical name recognition.   
 
Through extensive experiments, we have following findings.  First, adaptation of the part-
of-speech tagger to the biomedical domain is critical for high performance biomedical 
name recognition.  Second, the part-of speech feature, the head noun feature and the 
cascaded name recognition methods are very useful for biomedical name recognition.  
Third, the special verb trigger cannot lead to positive effect in our model.  Fourth, in our 
model, at least 200K words are required in the training data to achieve reliable 
performance.  
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We can also find that although name recognition in biomedical domain is difficult, we can 
make use of the underlying information by analyzing the domain in detail.  Experimental 
results prove that our model performs well on the GENIA corpus and outperforms 
previous best published system on the same training and test data.  Further analysis shows 
that with much higher performance can be expected with a more consistently annotated 
corpus and a reasonable dictionary. 
 
 
6.2 Future Work 
From the aspect of biomedical names, further explorations can be made on the 
complicated constructions in the biomedical documents.  One possible way is to develop 
effective patterns for conjunction and disjunction construction.  In addition, existing 
public resources and databases are potential information sources that can be integrated in 
biomedical name recognition. 
 
From the machine learning point of view, since names in the biomedical domain are 
constantly changing and there are many sub-domains that people are interested in, we 
should try to reduce the human work, such as annotation of large corpus, for supervised 
machine learning approaches.  One possible solution is unsupervised or semi-supervised 
methods, e.g. co-training and active learning, etc., which try to get high performance by 
requiring the human annotation as little as possible.  
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6.3 Dissemination of Results 
This thesis presents a coherent work on the explorations of the biomedical name 
recognition.   The work on the analysis of biomedical names, the exploration of the feature 
set, and the proposal of abbreviation recognition and post-processing rule approach for 
cascaded name recognition methods is covered in our paper published in the Proceedings 
of the ACL 2003 Workshop on Natural Language Processing in Biomedicine. [Dan et al. 
2003]  The work on the analysis of characteristic of biomedical names, the back-off HMM 
model, the further experiments on the feature set and the error analysis is covered in our 
paper accepted by the Bioinformatics. [Zhou et al. 2003]  The work on the HMM-based 
iterative recognition approach concerning about the cascaded name recognition is to be 
published in the Journal of Biomedical Informatics, Special Issue on Natural Language 
Processing in Biomedicine: Aims, Achievements and Challenge. [Zhang et al. 2004] 
 
Furthermore, a system covering all parts in this thesis is implemented and a web-demo can 
be accessed at http://textmining.i2r.a-star.edu.sg/NLS/demo.htm. 
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The GENIA Ontology 
+---+-source-+-natural-+-organism-+-multi-cell organism  
    |        |         |          +-mono-cell organism  
    |        |         |          +-virus  
    |        |         | 
    |        |         +-body part  
    |        |         +-tissue  
    |        |         +-cell type  
    |        |         +-cell component  
    |        |         +-other (natural source)  
    |        | 
    |        +-artificial-+-cell line  
    |                     +-other (artificial source)  
    | 
    +-substance-+-compound-+-organic-+-amino acid-+-protein-+-protein family or group  
    |           |          |         |            |         +-protein complex  
    |           |          |         |            |         +-individual protein molecule  
    |           |          |         |            |         +-subunit of protein complex  
    |           |          |         |            |         +-substructure of protein  
    |           |          |         |            |         +-domain or region of protein  
    |           |          |         |            | 
    |           |          |         |            +-peptide  
    |           |          |         |            +-amino acid monomer  
    |           |          |         | 
    |           |          |         +-nucleic acid-+-DNA-+-DNA family or group  
    |           |          |         |              |     +-individual DNA molecule  
    |           |          |         |              |     +-domain or region of DNA  
    |           |          |         |              | 
    |           |          |         |              +-RNA-+-RNA family or group  
    |           |          |         |              |     +-individual RNA molecule  
    |           |          |         |              |     +-domain or region of RNA  
    |           |          |         |              | 
    |           |          |         |              +-polynucleotide  
    |           |          |         |              +-nucleotide  
    |           |          |         |  
    |           |          |         +-lipid d  -+-steroi
    |           |          |         +-carbohydrate  
    |           |          |         +-other (organic compounds)  
    |           |          |        
    |           |          +-inorganic  
    |           +-atom  
    +-other 
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